SCHEMBL2384170

SCHEMBL2384170

CC(NC(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
EGFR P00533 1/20 0.48
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.42
HIF1A Q16665 2/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
BBOX1 O75936 2/20 0.40
EGLN1 Q9GZT9 2/20 0.40
FTO Q9C0B1 1/20 0.40
MAP3K5 Q99683 1/20 0.40
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384168 1.00 L3MBTL1 (0.51) L3MBTL1EGFRMEN1KMT2ANPC1
SCHEMBL12254536 0.91 L3MBTL1 (0.48) L3MBTL1EGFRMEN1KMT2ANPC1
SCHEMBL2385869 0.89 L3MBTL1 (0.47) L3MBTL1EGFRMEN1KMT2ANPC1
SCHEMBL2385866 0.89 L3MBTL1 (0.47) L3MBTL1EGFRMEN1KMT2ANPC1
SCHEMBL2384054 0.87 L3MBTL1 (0.52) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL2384050 0.87 L3MBTL1 (0.52) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL2382505 0.86 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL2382509 0.86 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL2382478 0.86 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL2382482 0.86 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4035/4885EGFR 4278/4885MEN1 3474/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885EGFR 4080/4885MEN1 3364/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885EGFR 4080/4885MEN1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.